STSS Quote, Financials, Valuation and Earnings

Agenus, Inc. has a net margin of -4601.72% compared to Sharps Technology, Inc.'s net margin of -116.82%. Sharps Technology, Inc.'s return on equity of -111.89% beat Agenus, Inc.'s return on equity of --.

Sharps Technology, Inc. has a consensus price target of $22.00, signalling upside risk potential of 727.07%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 203.78%. Given that Sharps Technology, Inc. has higher upside potential than Agenus, Inc., analysts believe Sharps Technology, Inc. is more attractive than Agenus, Inc..

Sharps Technology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.510, suggesting its more volatile than the S&P 500 by 51.01%.

Sharps Technology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sharps Technology, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.

Sharps Technology, Inc. quarterly revenues are $2.3M, which are smaller than Agenus, Inc. quarterly revenues of $30.2M. Sharps Technology, Inc.'s net income of -$105.3M is lower than Agenus, Inc.'s net income of $63.9M. Notably, Sharps Technology, Inc.'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sharps Technology, Inc. is 6.72x versus 1.03x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

AIM ImmunoTech has a net margin of -4601.72% compared to Sharps Technology, Inc.'s net margin of -10571.43%. Sharps Technology, Inc.'s return on equity of -111.89% beat AIM ImmunoTech's return on equity of -256.33%.

Sharps Technology, Inc. has a consensus price target of $22.00, signalling upside risk potential of 727.07%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Sharps Technology, Inc., analysts believe AIM ImmunoTech is more attractive than Sharps Technology, Inc..

Sharps Technology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.

Sharps Technology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sharps Technology, Inc. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.

Sharps Technology, Inc. quarterly revenues are $2.3M, which are larger than AIM ImmunoTech quarterly revenues of $35K. Sharps Technology, Inc.'s net income of -$105.3M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, Sharps Technology, Inc.'s price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sharps Technology, Inc. is 6.72x versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.

Armata Pharmaceuticals, Inc. has a net margin of -4601.72% compared to Sharps Technology, Inc.'s net margin of -2301.55%. Sharps Technology, Inc.'s return on equity of -111.89% beat Armata Pharmaceuticals, Inc.'s return on equity of --.

Sharps Technology, Inc. has a consensus price target of $22.00, signalling upside risk potential of 727.07%. On the other hand Armata Pharmaceuticals, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 51.52%. Given that Sharps Technology, Inc. has higher upside potential than Armata Pharmaceuticals, Inc., analysts believe Sharps Technology, Inc. is more attractive than Armata Pharmaceuticals, Inc..

Sharps Technology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Armata Pharmaceuticals, Inc. has a beta of 1.240, suggesting its more volatile than the S&P 500 by 23.97%.

Sharps Technology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sharps Technology, Inc. pays -- of its earnings as a dividend. Armata Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Sharps Technology, Inc. quarterly revenues are $2.3M, which are larger than Armata Pharmaceuticals, Inc. quarterly revenues of $1.2M. Sharps Technology, Inc.'s net income of -$105.3M is lower than Armata Pharmaceuticals, Inc.'s net income of -$26.7M. Notably, Sharps Technology, Inc.'s price-to-earnings ratio is -- while Armata Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sharps Technology, Inc. is 6.72x versus 49.27x for Armata Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protalix Biotherapeutics, Inc. has a net margin of -4601.72% compared to Sharps Technology, Inc.'s net margin of 13.19%. Sharps Technology, Inc.'s return on equity of -111.89% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.

Sharps Technology, Inc. has a consensus price target of $22.00, signalling upside risk potential of 727.07%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 528.57%. Given that Sharps Technology, Inc. has higher upside potential than Protalix Biotherapeutics, Inc., analysts believe Sharps Technology, Inc. is more attractive than Protalix Biotherapeutics, Inc..

Sharps Technology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.

Sharps Technology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sharps Technology, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Sharps Technology, Inc. quarterly revenues are $2.3M, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Sharps Technology, Inc.'s net income of -$105.3M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Sharps Technology, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 25.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sharps Technology, Inc. is 6.72x versus 2.23x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.